# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹552 Cr** (Q1 FY'26) (+8%) · **₹502 Cr** (Q1 FY'25) * EBITDA: ₹69.5 Cr (Q1 FY'26) (+19.5%) · ₹58.2 Cr (Q1 FY'25) * PAT: ₹34 Cr (Q1 FY'26) (+14.4%) · ₹29.7 Cr (Q1 FY'25) * **Cash-adjusted PAT:** **₹55 Cr** (Q1 FY'26) (+16%) · **₹47 Cr** (Q1 FY'25) ## B. Revenue Growth * **Strong Start to FY'26:** Robust top-line growth driven by integrated business model, improved capacity utilization, and operational efficiencies despite macro headwinds. * **Cost & Inventory Dynamics:** Raw material costs rose, but **₹12 Cr increase in finished goods inventory** partially explains the variance, suggesting near-term working capital build. ## C. EBITDA Margin * **Sustained Margin Expansion:** EBITDA margin improved significantly on both quarterly and run-rate basis, supported by favorable product mix and cost optimization. * **Forward Outlook:** Management expects margin progression to **14–15%** in the near term, reflecting confidence in continued operational leverage. ## D. Profit After Tax * **Bottom-Line Resilience:** PAT surged on a low base, with margin improvement underscoring disciplined financial management and core profitability strength. ## E. Cash Flow * **Healthy Cash Conversion:** Cash-adjusted PAT outpaced net income growth, signaling strong cash generation and operational cash flow resilience. --- # 2. Product & Segment Performance ## A. Key Figures * API Price Realizations: USD 9–10 Ibuprofen · USD 3–3.5 Paracetamol · USD 2.5–3 Metformin * **In-House Consumption:** **75–80%** IBB · **40%** Acetic Anhydride · **0%** Ethyl Acetate * **Non-Ibuprofen Revenue Share:** **34%** in 1Q * **Chemical Segment EBITDA Margin:** **5–6%** projected for FY'26 * **Paracetamol Export Premium:** **10–20% higher** than domestic prices ## B. API Revenue Mix * **Diversifying Portfolio:** Non-Ibuprofen APIs now represent a **third of revenue**, with growth driven by capacity utilization, regulatory clearances, and expansion into regulated markets. * **Pricing Clarity:** Paracetamol realization reflects a blended domestic-export mix, with exports commanding a **10–20% premium**, supporting margin resilience. * **Captive Integration:** High in-house consumption of IBB and partial use of Acetic Anhydride underscore vertical integration, while Ethyl Acetate is fully merchant-market oriented. ## C. Chemical Segment Margin * **Challenging Pricing Environment:** Chemical segment faces soft demand and subdued pricing, particularly for Acetic Anhydride, though cost advantages from backward integration provide cushioning. * **Margin Outlook:** Segment expected to deliver **5–6% EBITDA margin** in FY'26, consistent with blended company guidance, despite weak market sentiment. ## D. Capacity Utilization * **Stable Demand Trends:** Ibuprofen demand remains steady, while Paracetamol shows gradual uptick, mirrored in improving plant utilization. * **Growth Catalyst:** Unit 9B set for commercial commissioning by **December 2025**, poised to expand non-Ibuprofen API output with ready demand and product readiness. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Paracetamol Plant Capacity:** **10,800 MTPA** (fully automated, backward-integrated) * **Metformin Capacity:** **7,600 MTPA** (currently **>90% utilized**) * **Minoxidil Capacity:** **120 tonnes** (target), with **peak revenue of ₹50–60 Cr** expected * **New Metformin Addition:** **+4,000 MTPA** via repurposing old Paracetamol plant * **Current Utilization:** **Paracetamol 34% (Q1)** → targeted **60% by Q3 FY'26**; **Minoxidil plant ramp-up to 55–60% in FY'26** ## B. New Plant Ramp-up * **Automated Paracetamol Export Launch:** The new 10,800 MTPA integrated plant has commenced exports to European and regulated markets, marking a strategic upgrade in global competitiveness. * **Ramp-up Trajectory:** Initial capacity utilization of 55–60% expected in FY'26, with optimal levels targeted the following year, supported by rising internal demand and export momentum. ## C. Expansion Projects * **Minoxidil Scale-up Underway:** Unit 9Bs conversion and repurposing of former Gabapentin facility reflect strong customer demand and de-risked development due to existing validation data. * **Multi-Pronged Capacity Additions:** Expansion includes new Minoxidil line and **+4,000 MTPA Metformin capacity**, enhancing product diversification and volume leverage. * **Land & Regulatory Progress:** Environmental clearance pending for **100-acre site** near Chandigarh-Bhatinda highway; public hearing complete and ministry meeting held—next step for future chemical/API ambitions. ## D. Backward Integration * **Integrated Cost Advantage:** Backward integration in para aminophenol and Acetic Anhydride supports Paracetamol scale-up, with **Acetic Anhydride primarily consumed internally** amid rising captive needs. * **Internal Consumption Growth:** Increased Paracetamol output will drive higher captive use of Acetic Anhydride, while chemical units support Ibuprofen and other API production, improving margin resilience. * **High Utilization Across Portfolio:** Metformin runs at **over 90% capacity**, while Clopidogrel and Pantoprazole reach **70–80%**, underscoring strong domestic demand tailwinds. --- # 4. Geography & Market Mix ## A. Key Figures * **Revenue Split:** 75% domestic · 25% export * **Export Target:** 40% of total revenue within two years * **Ibuprofen Exports:** 70% to regulated markets (Europe, LATAM) · 25–30% to non-regulated markets * **Acetic Anhydride Price Differential:** **5%–10%** premium in regulated vs. non-regulated markets ## B. Export Strategy & Diversification * **Portfolio Rebalancing:** Strategic shift toward a **50-50 split between Ibuprofen and non-Ibuprofen APIs**, with focus on higher-value regulated markets. * **Geographic Expansion:** Targeting **40% export penetration** across chemicals and pharmaceuticals, driven by regulatory approvals and product reallocation. * **Market Prioritization:** Deliberate move to redirect **Clopidogrel** and **Pantoprazole Sodium** from domestic to **regulated international markets** for improved realizations. ## C. Regional Demand Trends * **Stable Overall Demand:** Non-Ibuprofen APIs — including **Metformin, Paracetamol, Fenofibrate** — show strong traction with **optimum capacity utilization**. * **Paracetamol Recovery:** Demand sustained **above pre-COVID levels** with low pricing, reflecting structural demand resilience. * **Europe Strength:** Solid demand momentum in pharma and chemicals underpinned by **CEP certifications** and ongoing customer approvals. * **Middle East Weakness:** Ethyl Acetate exports continue but face **bottomed-out pricing** and subdued demand. * **Monetization Strategy:** External sales of Acetic Anhydride limited to **surplus volumes** post internal consumption; no formal market expansion targets. --- # 5. Regulatory & Approval Progress ## A. Key Figures * **USFDA Approvals:** **Multiple products approved**, including Metformin, with some granted **without physical inspections** * **REACH Registration:** **Acetic Anhydride successfully registered** under EU REACH, enabling EU market expansion ## B. USFDA & DMF Status * **Pipeline Momentum:** New products including Clopidogrel, Pantoprazole, and Fenofibrate advancing into regulated global markets amid ongoing customer audits and compliance scaling. * **Active Regulatory Engagement:** DMF under active review by USFDA following recent approvals of Fenofibrate and Levetiracetam, with queries being addressed. ## C. EU GMP Re-inspection * **Inspection Readiness:** Facility previously inspected twice by USFDA; successful audits by ANVISA and EU GMP support reliance pathways and reduce redundant inspection burden. * **Upcoming Milestone:** EU GMP re-inspection scheduled for **November**, with mutual recognition agreements expected to support favorable outcomes. ## D. REACH Registration * **Strategic Market Access:** REACH clearance for Acetic Anhydride strengthens IOL’s specialty chemicals positioning and unlocks targeted expansion in high-value European segments. --- # 6. Risks & Regulatory Exposure ## A. China Import Dependence * **Critical Supply Chain Dependency:** DCDA, a key raw material for Metformin, remains entirely imported from China due to absence of domestic availability. ## B. Tariff Uncertainty * **Low Current Tariff Risk:** API segment has not been subject to any implemented tariffs to date; however, uncertainty persists around potential future U.S. trade actions under a possible Trump administration. ## C. Pricing Pressure * **Stable Demand with Selective Pricing Challenges:** Pharmaceutical API demand remains steady across most categories, though isolated products face ongoing pricing pressure, with signs of stabilization in select segments where prices have bottomed out. --- # 7. Guidance & Outlook ## A. Key Figures * **Non-Ibuprofen API Revenue:** **₹900–1,000 Cr** peak potential in 2–3 years (from ~₹500 Cr) * **Near-Term Non-Ibuprofen Target:** **₹800–900 Cr** in 2–3 years * **Revenue Guidance:** **10% growth** for current year, targeting **10–15% blended growth** * **Long-Term Revenue Target:** **₹2,000 Cr** from Ibuprofen and non-Ibuprofen APIs within 2 years * **FY26 CAPEX:** **₹150–200 Cr** (growth, infrastructure, automation, land) * **EBITDA Margin Guidance:** **14–15%** (including other income) ## B. Revenue Forecast * **Strategic Diversification:** Clear pivot toward balanced **50:50 revenue split** between Ibuprofen and non-Ibuprofen APIs, signaling reduced dependency on legacy products. * **Growth Trajectory:** Near-term non-Ibuprofen revenue target of ₹800–900 Cr reflects **strong double-digit expansion** and successful scaling of new API portfolio. * **Current Year Momentum:** Despite missing ₹600 Cr mark by a narrow margin (₹587 Cr), management expects to **approach or exceed target** in remaining quarters, underpinning confidence in demand and execution. ## C. Margin Target * **Margin Resilience:** Full-year EBITDA margin guidance of 14–15% reaffirmed, indicating stable cost control and operating leverage despite growth investments. ## D. CAPEX Plan * **Sustained Investment:** FY26 CAPEX set at ₹150–200 Cr, consistent with prior years, focused on **automation, land acquisition, and infrastructure** to support long-term capacity. * **Execution Transparency:** Growth-related CAPEX details to be disclosed **quarterly**, ensuring visibility into project progression without altering overall capital intensity.